SLG
62
-4
LLY
47
-4
RHI
52
2
GM
57
2
HBAN
45
-2
DFS
56
2
KHC
45
-4
URI
59
6
EXC
54
-2
UHS
54
-4
EW
16
-9
CCL
67
2
RF
50
3
PFE
33
-2
PRGO
48
-2
AIG
53
2
MET
51
4
MA
69
2
DUK
64
-5
MMC
62
-5
SLG
62
-4
LLY
47
-4
RHI
52
2
GM
57
2
HBAN
45
-2
DFS
56
2
KHC
45
-4
URI
59
6
EXC
54
-2
UHS
54
-4
EW
16
-9
CCL
67
2
RF
50
3
PFE
33
-2
PRGO
48
-2
AIG
53
2
MET
51
4
MA
69
2
DUK
64
-5
MMC
62
-5
Financhill
Back

EyePoint Pharmaceuticals 10K Form

Buy
63

EYPT
EyePoint Pharmaceuticals

Last Price:
8.92
Seasonality Move:
-10.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive EYPT News And Ratings

See the #1 stock for the next 7 days that we like better than EYPT

EYPT Financial Statistics

Sales & Book Value

Annual Sales: $46.02M
Cash Flow: $-21.08M
Price / Cash Flow: 0
Annual Sales: $4.38
Price / Book: 2.06

Profitability

EPS (TTM): -1.78000
Net Income (TTM): $-86.82M
Gross Margin: $41.39M
Return on Equity: -50.45%
Return on Assets: -32.29%

EyePoint Pharmaceuticals Earnings Forecast

Key EyePoint Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 16 years for EYPT is 89.93%.
  • The Selling, General & Administrative Expenses for EYPT have been equal to 112.55% of Gross Profit Margin.
  • The Research & Development expenses have been 140.51% of Revenue.
  • The Interest Expense is -1.76% of Operating Income.
  • The Net Earning history of EYPT is -153.84% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 10 years.

EyePoint Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: EYPT
CUSIP: 30233G
Website: eyepointpharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.75
Quick Ratio: 4.53

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

EYPT Technical Analysis vs Fundamental Analysis

Buy
63
EyePoint Pharmaceuticals (EYPT) is a Buy

Is EyePoint Pharmaceuticals a Buy or a Sell?